RARE-19. MULTICENTER, PHASE 2 STUDY OF BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY

Vestibular schwannomas (VSs) in patients with neurofibromatosis 2 (NF2) are associated with hearing loss. Recently published data from a prospective clinical trial showed that bevacizumab treatment at a fixed dose of 7.5 mg/kg every 3 weeks was associated with hearing improvement and tumor shrinkage...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neuro Oncol
Hoofdauteurs: Plotkin, Scott, Tonsgard, James, Ullrich, Nicole, Allen, Jeffrey, Blakeley, Jashri, Rosser, Tena, Campian, Jian, Clapp, Wade, Fisher, Michael, Cutter, Gary, Korf, Bruce, Packer, Roger, Thomas, Coretta, Karjannis, Matthias
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2017
Onderwerpen:
Abstracts
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5691935/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.868
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items